NASDAQ:PLRX

Pliant Therapeutics (PLRX) Stock Forecast, Price & News

$22.88

-0.21 (-0.91%)

(As of 11:21 AM ET)

Compare

Today's Range: $22.66
▼
$23.24
50-Day Range: $20.99
▼
$30.56
52-Week Range: $6.37
▼
$36.64

Volume: 50,822 shs
Average Volume: 809,388 shs
Market Capitalization: $1.35 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $47.83

Pliant Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 107.2% Upside
$47.83 Price Target
Short Interest: Bearish
10.41% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.73
Upright™ Environmental Score
News Sentiment: 1.20
Based on 3 Articles This Week
Insider Trading: Selling Shares
$1.71 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.99) to ($3.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

172nd out of 981 stocks

Pharmaceutical Preparations Industry

75th out of 484 stocks

4.5

Analyst's Opinion

Consensus Rating
Pliant Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $47.83, Pliant Therapeutics has a forecasted upside of 107.2% from its current price of $23.09.
Amount of Analyst Coverage
Pliant Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
10.41% of the outstanding shares of Pliant Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Pliant Therapeutics has a short interest ratio ("days to cover") of 8.7.
Change versus previous month
Short interest in Pliant Therapeutics has recently increased by 48.43%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Pliant Therapeutics does not currently pay a dividend.
Dividend Growth
Pliant Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Pliant Therapeutics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Pliant Therapeutics is -0.73.

2.3

News and Social Media Coverage

News Sentiment
Pliant Therapeutics has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Pliant Therapeutics this week, compared to 4 articles on an average week.
Search Interest
Only 1 people have searched for PLRX on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pliant Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,705,880.00 in company stock.
Percentage Held by Insiders
Only 5.60% of the stock of Pliant Therapeutics is held by insiders.
Percentage Held by Institutions
97.52% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Pliant Therapeutics are expected to decrease in the coming year, from ($2.99) to ($3.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pliant Therapeutics is -8.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pliant Therapeutics is -8.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Pliant Therapeutics has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Pliant Therapeutics (NASDAQ:PLRX) Stock

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Receive PLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PLRX Stock News Headlines

June 5, 2023 | finance.yahoo.com

Investors in Pliant Therapeutics (NASDAQ:PLRX) have seen splendid returns of 253% over the past year

June 2, 2023 | americanbankingnews.com

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Buy" from Analysts

June 8, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.

May 25, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Pliant Therapeutics (PLRX)

May 24, 2023 | markets.businessinsider.com

Stifel Nicolaus Sticks to Their Buy Rating for Pliant Therapeutics (PLRX)

May 24, 2023 | finance.yahoo.com

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

May 23, 2023 | seekingalpha.com

Pliant Therapeutics: Trading In Oversold Territory, Buying The Dip

May 22, 2023 | americanbankingnews.com

Canaccord Genuity Group Initiates Coverage on Pliant Therapeutics (NASDAQ:PLRX)

June 8, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

May 20, 2023 | americanbankingnews.com

Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $21.53

May 17, 2023 | americanbankingnews.com

Brokers Offer Predictions for Pliant Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:PLRX)

May 17, 2023 | americanbankingnews.com

Pliant Therapeutics (NASDAQ:PLRX) Stock Rating Reaffirmed by Cantor Fitzgerald

May 16, 2023 | markets.businessinsider.com

Stifel Nicolaus Sticks to Its Buy Rating for Pliant Therapeutics (PLRX)

May 16, 2023 | americanbankingnews.com

Brokers Offer Predictions for Pliant Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:PLRX)

May 12, 2023 | msn.com

RBC Capital Maintains Pliant Therapeutics (PLRX) Outperform Recommendation

May 12, 2023 | americanbankingnews.com

HC Wainwright Trims Pliant Therapeutics (NASDAQ:PLRX) Target Price to $50.00

May 11, 2023 | msn.com

Oppenheimer Maintains Pliant Therapeutics (PLRX) Outperform Recommendation

May 11, 2023 | markets.businessinsider.com

SVB Securities Keeps Their Buy Rating on Pliant Therapeutics (PLRX)

May 11, 2023 | americanbankingnews.com

Pliant Therapeutics (NASDAQ:PLRX) Price Target Raised to $51.00 at Oppenheimer

May 10, 2023 | msn.com

Recap: Pliant Therapeutics Q1 Earnings

May 10, 2023 | markets.businessinsider.com

BTIG Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)

May 10, 2023 | finanznachrichten.de

Pliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 9, 2023 | finance.yahoo.com

Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates

May 9, 2023 | finance.yahoo.com

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 6, 2023 | americanbankingnews.com

FY2023 EPS Estimates for Pliant Therapeutics, Inc. (NASDAQ:PLRX) Raised by Analyst

May 6, 2023 | americanbankingnews.com

Brokerages Set Pliant Therapeutics, Inc. (NASDAQ:PLRX) PT at $47.64

May 5, 2023 | americanbankingnews.com

Research Analysts Issue Forecasts for Pliant Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:PLRX)

See More Headlines

PLRX Price History

30 days | 90 days | 365 days | Advanced Chart

PLRX Company Calendar

Last Earnings: 5/09/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PLRX
CUSIP: N/A
CIK: 1746473
Web: pliantrx.com
Phone: 650-481-6770
Fax: N/A
Employees: 91
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $47.83
High Stock Price Forecast: $63.00
Low Stock Price Forecast: $33.00
Forecasted Upside/Downside: +107.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.86)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-123,320,000.00
Net Margins: -1,359.22%
Pretax Margin: -1,359.22%
Return on Equity: -39.05%
Return on Assets: -35.16%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 25.41
Quick Ratio: 25.41

Sales & Book Value

Annual Sales: $9.69 million
Price / Sales: 140.97
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.43 per share
Price / Book: 3.59

Miscellaneous

Outstanding Shares: 59,160,000
Free Float: 55,843,000
Market Cap: $1.37 billion
Optionable: Not Optionable
Beta: 1.40

Key Executives

Dr. Bernard Coulie M.B.A. (Age 56)
M.D., MBA, Ph.D., Pres, CEO & Director
Comp: $889.01k

Dr. Keith Lamont Cummings M.B.A. (Age 45)
M.D., Chief Financial Officer
Comp: $606.12k

Mr. Mike Ouimette (Age 49)
Gen. Counsel & Corp. Sec.
Comp: $537.99k

Mr. Johannes P. Hull (Age 47)
Chief Bus. Officer
Comp: $582.49k

Dr. Éric Lefebvre M.D. (Age 58)
Chief Medical Officer
Comp: $713.81k

Dr. Rik Derynck
Scientific Founder & Member of Scientific Advisory Board

Mr. Dean Sheppard M.D.
Scientific Founder & Member of Scientific Advisory Board

Mr. Bill DeGrado Ph.D.
Scientific Founder & Member of Scientific Advisory Board

Mr. Hal Chapman M.D.
Scientific Founder & Member of Scientific Advisory Board

Mr. Craig D. Muir
Interim Chief Technology Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PLRX Stock - Frequently Asked Questions

Should I buy or sell Pliant Therapeutics stock right now?: 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PLRX shares.
View PLRX analyst ratings or view top-rated stocks.
What is Pliant Therapeutics' stock price forecast for 2023?: 11 brokers have issued 1-year price objectives for Pliant Therapeutics' shares. Their PLRX share price forecasts range from $33.00 to $63.00. On average, they predict the company's share price to reach $47.83 in the next twelve months. This suggests a possible upside of 107.2% from the stock's current price.
View analysts price targets for PLRX or view top-rated stocks among Wall Street analysts.
How have PLRX shares performed in 2023?: Pliant Therapeutics' stock was trading at $19.33 at the beginning of the year. Since then, PLRX stock has increased by 19.5% and is now trading at $23.09.
View the best growth stocks for 2023 here.
Are investors shorting Pliant Therapeutics?: Pliant Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 6,160,000 shares, an increase of 48.4% from the April 30th total of 4,150,000 shares. Based on an average daily volume of 708,200 shares, the short-interest ratio is presently 8.7 days.
View Pliant Therapeutics' Short Interest.
When is Pliant Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our PLRX earnings forecast.
How were Pliant Therapeutics' earnings last quarter?: Pliant Therapeutics, Inc. (NASDAQ:PLRX) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by $0.01. The business earned $1.33 million during the quarter, compared to analyst estimates of $1.96 million. Pliant Therapeutics had a negative trailing twelve-month return on equity of 39.05% and a negative net margin of 1,359.22%.
What ETFs hold Pliant Therapeutics' stock?: ETFs with the largest weight of Pliant Therapeutics (NASDAQ:PLRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), iShares Micro-Cap ETF (IWC), BlackRock Future Health ETF (BMED) and Invesco Nasdaq Biotechnology ETF (IBBQ).

What other stocks do shareholders of Pliant Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), Ampio Pharmaceuticals (AMPE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).
When did Pliant Therapeutics IPO?: (PLRX) raised $90 million in an initial public offering (IPO) on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager.
What is Pliant Therapeutics' stock symbol?: Pliant Therapeutics trades on the NASDAQ under the ticker symbol "PLRX."
Who are Pliant Therapeutics' major shareholders?: Pliant Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (7.66%), CHI Advisors LLC (5.07%), Price T Rowe Associates Inc. MD (3.56%), BlackRock Inc. (3.09%), First Light Asset Management LLC (2.41%) and Jennison Associates LLC (2.08%). Insiders that own company stock include Bernard Coulie, Eric Lefebvre, Keith Lamont Cummings, Matthew Dunnigan and Mike Ouimette.
View institutional ownership trends.
How do I buy shares of Pliant Therapeutics?: Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Pliant Therapeutics' stock price today?: One share of PLRX stock can currently be purchased for approximately $23.09.
How much money does Pliant Therapeutics make?: Pliant Therapeutics (NASDAQ:PLRX) has a market capitalization of $1.37 billion and generates $9.69 million in revenue each year. The company earns $-123,320,000.00 in net income (profit) each year or ($2.86) on an earnings per share basis.
How can I contact Pliant Therapeutics?: Pliant Therapeutics' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is pliantrx.com. The company can be reached via phone at 650-481-6770 or via email at ir@pliantrx.com.

This page (NASDAQ:PLRX) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial